Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;20(7):102846.
doi: 10.1016/j.autrev.2021.102846. Epub 2021 May 7.

CCR6-CCL20 axis as a therapeutic target for autoimmune diseases

Heikrujam Thoihen Meitei  1 , Nandadeep Jadhav  1 , Girdhari Lal  2
Affiliations
Review

CCR6-CCL20 axis as a therapeutic target for autoimmune diseases

Heikrujam Thoihen Meitei et al. Autoimmun Rev. 2021 Jul.

Abstract

Chemokine receptor CCR6 is expressed on various cells such as B cells, immature dendritic cells, innate lymphoid cells (ILCs), regulatory CD4 T cells, and Th17 cells. CCL20 is the only known high-affinity ligand that binds to CCR6 and drives CCR6+ cells' migration in tissues. CCL20 is mainly produced by epithelial cells, and its expression is increased by several folds under inflammatory conditions. Genome-wide association studies (GWAS) in patients with inflammatory bowel disease (IBD), psoriasis (PS), rheumatoid arthritis (RA), and multiple sclerosis (MS) showed a very strong correlation between the expression of CCR6 and disease severity. It has been shown that disruption of CCR6-CCL20 interaction by using antibodies or antagonists prevents the migration of CCR6 expressing immune cells at the site of inflammation and reduces the severity of the disease. This review discussed the importance of the CCR6-CCL20 axis in IBD, PS, RA, and MS, and recent advances in targeting the CCR6-CCL20 in controlling these autoimmune diseases.

Keywords: CCL20; CCR6; Mucosal tolerance; Regulatory CD4 T cells; Th17 cells.

PubMed Disclaimer